StatSure Diagnostic Systems, Inc.
SSUR
Other OTC0.00
USD
-0.05
- -
ISIN
US85771V2088
Return %
Stock
S&P500
1Y
- -
26.53
3Y
-98.62
76.60
5Y
-92.31
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Moshe Bodner
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1222 Avenue M Brooklyn NY United States of America 11230
- IPO Date
- Oct 31, 1994
- Website
- statsurediagnostics.com
- Similar Companies
- Business
- StatSure Diagnostic Systems, Inc. develops, manufactures, and markets rapid in-vitro diagnostic immunoassay tests primarily for the detection of sexually transmitted and infectious diseases. Its core product offerings include the SURE CHECK HIV 1/2 and Clearview Complete HIV 1/2 single-use diagnostic tests for visual detection of antibodies to HIV-1 and HIV-2. The company also produces patented oral-fluid specimen collection devices designed to improve accuracy, operator convenience, and reduce infection risk during specimen collection and handling. StatSure's products are sold domestically in the United States and internationally through distributors targeting clinical laboratories, hospitals, clinics, community-based organizations, and public health entities. The company operates within the diagnostic testing and healthcare segments. Founded in 1986, StatSure is headquartered in Brooklyn, New York. In the past two years, StatSure Diagnostic Systems has focused on expanding its diagnostic test portfolio and enhancing its product platforms for rapid immunoassay testing. It has pursued strategic equity financing rounds to support growth initiatives and product development efforts. Although no major recent acquisitions or partnerships have been publicly disclosed, the company continues to innovate and maintain a significant presence in the infectious disease testing market by leveraging its proprietary immunoassay technology. StatSure aims to broaden its geographic reach and clinical applications with ongoing product improvements and regulatory efforts to support broader point-of-care diagnostic solutions. StatSure Diagnostic Systems operates primarily in the United States with international distribution channels, addressing the needs of healthcare providers and public health organizations engaged in infectious disease detection and control. The company’s patented oral-fluid collection devices and rapid assay tests provide competitive advantages in ease of use and reliability. Its proprietary platforms support both existing products and facilitate the potential development of new immunoassay tests to meet evolving market demands.